{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:01:07Z","timestamp":1790870467744,"version":"4.1.0"},"reference-count":10,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,8,14]],"date-time":"2015-08-14T00:00:00Z","timestamp":1439510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Head &amp; Neck"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Increased somatostatin receptor (SSTR) expression in patients with undifferentiated nasopharyngeal carcinoma (NPC) has been demonstrated with receptor autoradiography, <jats:sup>111<\/jats:sup>In\u2010Octreotide scintigraphy, and <jats:sup>68<\/jats:sup>Ga\u2010DOTA\u2010TOC positron emission tomography (PET)\/CT imaging. We sought to compare and correlate the uptake of fluorodeoxyglucose (FDG) and DOTA\u2010NOC in undifferentiated NPC to ascertain the possible role of <jats:sup>68<\/jats:sup>Ga\u2010DOTA\u2010NOC PET\/CT as a new imaging biomarker and to assess whether targeted peptide receptor radionuclide therapy is a feasible treatment option.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>After obtaining approval from our institutional review board, 4 patients with biopsy proven nonkeratinizing undifferentiated NPC who had just undergone routine staging\/restaging <jats:sup>18<\/jats:sup>F\u2010FDG PET\/CT imaging were prospectively and consecutively recruited for <jats:sup>68<\/jats:sup>Ga\u2010DOTA\u2010NOC PET\/CT imaging. Of these 4 patients, 3 were newly diagnosed with untreated NPC, whereas 1 patient was diagnosed with a case of recurrent NPC with previous treatment. These patients subsequently underwent <jats:sup>68<\/jats:sup>Ga\u2010DOTA\u2010NOC PET\/CT within 10 days from the <jats:sup>18<\/jats:sup>F\u2010FDG PET\/CT to ensure lesion comparability. Tracer uptake in tumor lesions were assessed visually and semiquantitatively by measuring maximum standardized uptake values (SUVmax).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 12 FDG\u2010avid lesions of which 7 showed avid uptake of DOTA\u2010NOC greater than liver uptake, whereas 5 showed low uptake of DOTA\u2010NOC less than liver uptake. Subset analysis of the FDG\u2010avid lesions at the primary and recurrent sites showed that all the FDG\u2010avid primary tumors in the nasopharynx showed avid uptake of DOTA\u2010NOC. On the contrary, the case of recurrent NPC showed avid FDG uptake but low DOTA\u2010NOC uptake. Subset analysis of the suspicious FDG\u2010avid cervical lymph nodes showed that 50% of them demonstrated avid DOTA\u2010NOC uptake greater than liver uptake, whereas the remaining demonstrated low\u2010grade DOTA\u2010NOC uptake less than liver uptake. The 2 subcentimeter cervical lymph nodes that showed low\u2010grade uptake of FDG lower than mediastinal blood pool activity were deemed to be reactive\/inflammatory and showed low\u2010grade uptake of DOTA\u2010NOC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study highlights the potential of <jats:sup>68<\/jats:sup>Ga\u2010DOTA\u2010peptide PET\/CT as a new molecular biomarker for newly diagnosed undifferentiated NPC, and less so for recurrent NPC and metastatic nodes. This potentially opens up new diagnostic and therapeutic options in the management of undifferentiated NPC. \u00a9 2015 Wiley Periodicals, Inc. <jats:italic>Head Neck<\/jats:italic> 38: E76\u2013E80, 2016<\/jats:p><\/jats:sec>","DOI":"10.1002\/hed.24164","type":"journal-article","created":{"date-parts":[[2015,8,14]],"date-time":"2015-08-14T14:43:51Z","timestamp":1439563431000},"source":"Crossref","is-referenced-by-count":19,"title":["<sup>68<\/sup>Ga\u2010DOTA\u2010peptide: A novel molecular biomarker for nasopharyngeal carcinoma"],"prefix":"10.1002","volume":"38","author":[{"given":"Lih Kin","family":"Khor","sequence":"first","affiliation":[{"name":"Department of Diagnostic Imaging National University Hospital  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi Yin","family":"Loi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging National University Hospital  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind Kumar","family":"Sinha","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging National University Hospital  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kian Ti","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and PET Singapore General Hospital  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boon Cher","family":"Goh","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology National University Hospital  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwok Seng","family":"Loh","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology National University Hospital  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suat\u2010Jin","family":"Lu","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and PET Centre Mount Elizabeth Hospital  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,8,14]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.48763"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-002-0693-y"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0b013e31817dec00"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2905-5"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2004.07.702"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq277"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1512-3"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-009-1297-4"},{"issue":"2","key":"e_1_2_6_10_1","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1023\/A:1027396313397","article-title":"Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy","volume":"10","author":"Krenning EP","year":"1999","journal-title":"Ann Oncol"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3012-y"}],"container-title":["Head &amp; Neck"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhed.24164","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhed.24164","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hed.24164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T03:08:02Z","timestamp":1695006482000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hed.24164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,14]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1002\/hed.24164"],"URL":"https:\/\/doi.org\/10.1002\/hed.24164","archive":["Portico"],"relation":{},"ISSN":["1043-3074","1097-0347"],"issn-type":[{"value":"1043-3074","type":"print"},{"value":"1097-0347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,14]]}}}